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Abstract Zaïre ebolavirus (ZEBOV) infection rapidly
outruns the host's immunity and leads to death within a
week. Fatal cases have been associated with an aberrant
innate, proinflammatory immune response followed by a
suppressed adaptive response leading to the rapid depletion
of peripheral NK cells and lymphocytes. A critical role for
NK cells has been suggested but not elucidated. In this
genetic study, we investigated the association of KIR
genotype with disease outcome by comparing genotypes
of a Gabonese control population, IgG+ contacts, survivors,
and fatalities of ZEBOV infection. We showed that the
activating KIR2DS1 and KIR2DS3 genes associate with
fatal outcome in Ebola virus infection. In addition, this
study brings supplemental evidence in favor of the
specificity of the IgG+ contact population. The outcome
of fulminating Ebola virus infection could depend in part
on the host's inherited KIR gene repertoire. This supports a
key role for KIRs in disease susceptibility to infections.
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Ebola virus, from the family Filoviridae, causes severe
hemorrhagic fever in humans and primates (Hoenen et al.
2006). The Zaïre ebolavirus (ZEBOV) species associates
with an 80% case-fatality rate. ZEBOV infection rapidly
outruns the host's immunity and leads to death within a
week. Severe cases are associated with aberrant innate,
proinflammatory immunity preceding a suppressed adaptive
response which leads to the rapid depletion of peripheral
natural killer (NK) cells and other lymphocytes (Baize et al.
1999, 2002; Leroy et al. 2000). A critical role for innate
host factors has been suggested, but the function of NK
cells during ZEBOV infection remains unclear.
We present a genetic study focusing on the influence of a
host factor, the killer immunoglobulin-like receptor (KIR)
repertoire, in this context of ZEBOV infection. KIRs are
members of the Ig-superfamily of type I membrane
proteins, expressed on the surface of NK cells and T-cell
subsets (Lanier 1998). Encoded by a family of highly
polymorphic genes, KIRs bind to HLA class I alleles, and
the complex integration of signals drive NK function
(Carrington and Martin 2006; Dohring and Colonna
1996).Thus, individual KIR haplotypes differ in number
and identity of genes, each haplotype including seven to 12
genes (Wilson et al. 2000;W i t te ta l .1999). Two
haplotypes are commonly defined: (1) the A haplotype
comprises seven KIR genes, including a unique activating
KIR gene KIR2DS4, and (2) B haplotypes are variable and
characterized by the presence of additional activating KIR
genes (Uhrberg et al. 1997; Valiante et al. 1997). Unrelated
individuals are therefore unlikely to express identical KIRs
(Shilling et al. 2002).
Following the model of major histocompatibility com-
plex studies, disease association studies have revealed
associations of KIR genes with disease. To date, these
studies have mainly targeted viral infections such as human
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mune, and inflammatory disorders (Khakoo et al. 2004;
Martin et al. 2002; Cook et al. 2006; Yen et al. 2001).
Activating genotypes generally appear to be beneficial
during viral infections, whereas they constitute more a risk
for susceptibility to autoimmunity and certain cancers
(Kulkarni et al. 2008). Our concern here was to evaluate
the association of KIR genotype with the outcome of
human ZEBOV infection, a fulminating disease in which
the innate immunity seems critical.
To investigate the influence of the KIR repertoire upon
the outcome of human EBOV infection, we compared KIR
genotype of laboratory-confirmed ZEBOV survivors to
fatalities. Samples from fatalities were previously obtained
during the Gabonese epidemics of 2001–2002 (Leroy et al.
2004). Survivors and contacts (IgG+, with no historic of the
disease) were sampled during retrospective campaigns
(Wauquier et al. 2009; Becquart et al. 2010). Contacts
(43% male; mean age, 41; range, 18–70) and controls (41%
male; mean age, 36; range, 18–57) were selected to match
for age and sex. All blood samples were retrieved with
informed and written consent. EBOV-IgG serostatus was
determined by ELISA as previously described (Ksiazek et
al. 1999). Genomic DNA was extracted using QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany) from
whole blood or PBMCs isolated using standard density
gradient centrifugation with Ficoll-Paque (Eurobio, les Ulis,
France). Genotyping was performed by polymerase chain
reaction using the KIR typing kit (Miltenyi Biotec, Inc.,
Auburn, CA, USA) following manufacturer's instructions.
Fifteen KIR genes and two pseudogenes were typed. In
total, tests were performed on samples from 21 survivors,
15 non-survivors, 68 contacts (IgG+), and 54 controls
(IgG−) of same geographical origin. Statistical analysis
used chi-squared test or Fisher's exact test to compare
results between each groups. A probability level of less
than 0.05 was considered statistically significant.
We studied KIR genotypes in four populations: (1)
healthy volunteers from rural regions of Gabon, tested anti-
ZEBOV IgG−, were used as controls; (2) healthy and anti-
ZEBOV IgG+ individuals, from regions where no cases of
ZEBOV infection have ever been reported, were defined as
contacts; and (3) patients that had fully recovered from all
symptoms (survivors) and (4) fatalities had all been
laboratory-confirmed during the epidemics. Percentages of
individuals carrying each particular KIR gene were calcu-
Table 1 Percentages of carriers of inhibitory, activating, and pseudogene KIR genes in a control Gabonese population and in contacts (IgG+),
survivors, and fatalities of Ebola virus infection
Control Control Contacts Survivors Fatalities
Senegal (n=54) (n=68) (n=21) (n=15)
(n=90) n % pn % pn % pn % p
2DL1 100 54 100.0 68 100.0 21 100.0 13 86.7 *
2DL2 55 35 64.8 40 58.8 12 57.1 11 73.3
2DL3 90 43 79.6 56 82.4 17 81.0 9 60.0
2DL4 100 54 100.0 68 100.0 21 100.0 15 100.0
2DL5all 52 39 72.2 48 70.6 13 61.9 13 86.7
2DL5A 31 57.4 34 50.0 11 52.4 9 60.0
2DL5B 38 70.4 48 70.6 13 61.9 10 66.7
3DL1 99 54 100.0 66 97.1 21 100.0 15 100.0
3DL2 100 54 100.0 68 100.0 21 100.0 15 100.0
3DL3 100 54 100.0 68 100.0 21 100.0 15 100.0
2DS1 13 10 18.5 14 20.6 1 4.8 7 46.7 *
, **
2DS2 42 31 57.4 35 51.5 9 42.9 10 66.7
2DS3 24 19 35.2 21 30.9 2 9.5 * 8 53.3 **
2DS4del 36 66.7 47 69.1 15 71.4 11 73.3
2DS4ins 44 81.5 41 60.3 * 19 90.5 11 73.3
2DS5 30 18 33.3 27 39.7 10 47.6 7 46.7
3DS1 4 4 7.4 8 11.8 2 9.5 1 6.7
2DP1 100 54 100.0 68 100.0 21 100.0 15 100.0
3DP1 100 54 100.0 68 100.0 21 100.0 15 100.0
*p<0.05 between studied group and controls; **p<0.05 between survivors and fatalities
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genotypes were distinguished (Fig. 1).
Percentages of KIR gene carriers in the Gabonese control
population were in accordance with those of another African
population from Senegal (Table 1), although Gabon is
situated in the Central African forests and mainly inhabited
by the Bantu, an ethnic population that highly differs from
the sub-Saharan population of Senegal (Denis et al. 2005).
The genotype most represented was the unique AA
homozygous genotype (Fig. 1). Contacts were otherwise
similar to controls only differing by a significantly lower
percentage of activating KIR2DS4 carriers (Table 1). Only
9.5% of survivors (vs 35.2% in controls) had the activating
KIR2DS3 gene. The frequency of AA profiles, containing
only one activating gene (2DS4), was highest in survivors
(33.3%) but lowest in fatalities (13.3%) (Fig. 1). Fatal cases
differed from controls by three genes. A higher proportion of
non-survivors possessed the activating KIR2DS1, whereas
two non-survivors lacked the inhibitory KIR2DL1. Interest-
ingly, KIR2DS1 and KIR2DS3 genes were also significantly
more frequent in fatalities (46.8% and 53.3%, respectively)
than in survivors (4.6% and 9.5%, respectively; Table 1),
thus indicating a potential effect of these activating KIRs in
fatal outcome. In the same way, KIR2DS1 has been
previously associated with susceptibility to psoriasis but also
protection against spontaneous abortion or development of
Hodgkin's lymphoma (Luszczek et al. 2004;H i b ye ta l .
2008;B e s s o ne ta l .2007). By contrast, KIR2DS3 was
significantly decreased among patients with microscopic
polyangiitis (Miyashita et al. 2006).
Finally, we found that the mean number of activating
KIR genes per genotype was lowest in survivors (2.1) and
highest in fatalities (3.2; data not shown). These values
were average for controls and contacts at 2.47 and 2.52,
respectively. Controls, contacts, survivors, and fatalities
presented similar mean number of inhibitory KIR genes per
genotype with 7.15, 7.19, 6.95, and 6.93, respectively.
These observations suggest that certain KIR combinations
could provide a permissive immune microenvironment
fostering fatal outcome.
2DL1 2DL2 2DL3 2DL4 2DL5 2DS1 2DS2 2DS3 2DS4 2DS5 3DL1 3DL2 3DL3 3DS1 2DP1 3DP1 n % (n=54) n % (n=68) n % (n=21) n % (n=15)
1A A 13 24.07 15 22.06 7 33.33 2 13.33
2 1 6.67
3 1 6.67
4 1 1.47
5 1 1.47
6 3 5.56 5 7.35
7 2 3.70 5 7.35 3 14.29 1 6.67
8 1 1.85
9 1 1.47
10 1 4.76
11 3 5.56 2 2.94 2 9.52
12 1 4.76
13 2 3.70 3 4.41 2 13.33
14 2 2.94
15 1 1.85
16 1 1.85
17 1 6.67
18 1 1.85
19 2 3.70 1 1.47 2 13.33
20 1 1.85 2 2.94
21 3 5.56 4 5.88 1 4.76 1 6.67
22 3 5.56 5 7.35 1 4.76
23 3 5.56 3 4.41 2 9.52
24 11 20.37 9 13.24 2 9.52 1 6.67
25 1 1.85
26 1 6.67
27 2 3.70 3 4.41
28 1 4.76
29 2 2.94 1 6.67
30 1 1.85 1 1.47 1 6.67
31 1 1.47
32 1 1.47
33 1 1.47
Non-survivors
AB/BB
KIR
Genotype
CTL IgG+ Survivors
Fig. 1 KIR genotype profiles observed in the Gabonese population, contacts (IgG+) group, survivors, and fatalities of Ebola virus infection
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specificity of the IgG+ contact population. If IgG positivity
was to be the result of cross-reaction with antibodies against
other common infections, this population would present the
same KIR repertoire as the controls. On the contrary, contacts
were characterized by KIR distribution that differed from
controls, survivors, and fatalities, defining a fourth category,
implying that this population results from either (1) simple
exposure to the virus (abortive infection), meaning that the
KIR repertoire here includes repertoires of both survivors and
fatalities, or (2) ZEBOV infection, then the KIR repertoire in
this population contributes to an asymptomatic, “hyper-
resistant” phenotype.
An activating KIR profile was associated with fatal
outcome. This deleterious effect seems linked to KIR2DS1
and KIR2DS3 genes that were by far more present amongst
non-survivors. KIR genes exhibit considerable sequence
diversity (Garcia et al. 2003). Fifteen alleles of KIR2DS1
and 13 alleles of KIR2DS3 have been described (http://
www.ebi.ac.uk/ipd/kir/index.html). This may influence ex-
pression, ligand binding, cytolysis, and cytokine secretion,
as described for other KIRs (Yawata et al. 2006).
Furthermore, KIRs are clonally expressed on NK cells in
a stochastic manner so that each NK cell clone expresses
only a portion of its KIR genome. Therefore, a substantial
fraction of a patient's NK cells may not express KIR2DS1
and KIR2DS3 even though they carry the corresponding
genes and thus still ignore ZEBOV-infected targets,
explaining the survival of certain patients which carry these
activating KIRs (Valiante et al. 1997).
It is generally thought that in the context of ZEBOV
infection, it is the over-activation of the immune
response that is responsible for the rapid depletion in
NK cells and lymphocytes. Our results support this
hypothesis, suggesting that the activity of KIR2DS1 and
KIR2DS3, in conjunction with the appropriate ligands,
may favor the activation status of the host's NK cells and
participate in the physiopathological process by exces-
sively destroying infected cells.
This study presents evidence that KIR2DS1 and
KIR2DS3 are associated with fatal outcome in Ebola virus
infection, supporting a key role for KIRs in disease
susceptibility to infections. It is therefore suggested that
NK cells, rapidly efficient after infection, may be critical
for either pathogenesis or recovery from this fatal disease.
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